Lorrain Daniel S. 4
4 · Contineum Therapeutics, Inc. · Filed Jan 31, 2025
Insider Transaction Report
Form 4
Lorrain Daniel S.
Chief Scientific Officer
Transactions
- Award
Stock Option (right to buy)
2025-01-31+3,700→ 3,700 total(indirect: By Spouse)Exercise: $9.79Exp: 2035-01-30→ Class A Common Stock (3,700 underlying) - Award
Stock Option (right to buy)
2025-01-31+110,000→ 110,000 totalExercise: $9.79Exp: 2035-01-30→ Class A Common Stock (110,000 underlying)
Footnotes (2)
- [F1]Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"). 25% of the option shares vest on January 1, 2026, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service.
- [F2]Options granted under the Plan in connection with Reporting Person's spouse's continuous service at the Company. 25% of the option shares vest on January 1, 2026, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's spouse's continuous service.